Principal Investigator

Carlos A Zarate, M.D.

National Institute of Mental Health (NIMH)

12 trials
4 recruiting now
1 compound

Therapeutic focus

Suicide
Depressive Disorder, Treatment-Resistant
Ketamine
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Excitatory Amino Acid Agents
Physiological Effects of Drugs
Depressive Disorder, Major
Depressive Disorder
Depression
Mental Disorders
Mood Disorders

Recruiting now (4)

NCT	Phase	Status	Compound	Sponsor
NCT06511908	Phase 2	Recruiting	—	National Institute of Mental Health (NIMH)
NCT03973268	Phase 1	Recruiting	—	National Institute of Mental Health (NIMH)
NCT03065335	Phase 1	Recruiting	—	National Institute of Mental Health (NIMH)
NCT02543983	Phase 2	Recruiting	—	National Institute of Mental Health (NIMH)

All trials (12)

NCT	Phase	Status	Compound	Sponsor
NCT06511908	Phase 2	Recruiting	—	National Institute of Mental Health (NIMH)
NCT03973268	Phase 1	Recruiting	—	National Institute of Mental Health (NIMH)
NCT03065335	Phase 1	Recruiting	—	National Institute of Mental Health (NIMH)
NCT02543983	Phase 2	Recruiting	—	National Institute of Mental Health (NIMH)
NCT04821271	Phase 2	Discontinued	TS-161	Taisho Pharmaceutical Co., Ltd.
NCT02484456	Phase 2	Completed	—	National Institute of Mental Health (NIMH)
NCT02049385	Phase 1/2	Discontinued	—	National Institute of Mental Health (NIMH)
NCT00088699	Phase 1/2	Completed	—	National Institute of Mental Health (NIMH)
NCT00086307	Phase 2	Completed	—	National Institute of Mental Health (NIMH)
NCT00078715	Phase 2	Completed	—	National Institute of Mental Health (NIMH)
NCT00055575	Phase 2	Discontinued	—	National Institute of Mental Health (NIMH)
NCT00054704	Phase 2	Discontinued	—	National Institute of Mental Health (NIMH)

Compounds studied

TS-161

Trial sites (1)

Bethesda, Maryland, United States

Investigator and site data mirrored fromClinicalTrials.gov (public domain).